InnoSerは、厳密に区画された部屋で構成される最先端の動物施設内でげっ歯類行動試験を実施しています。これらの部屋には、従来型および自動化スクリーニングの両方に対応した専用行動試験装置が設置されています。この戦略的な設備構成と厳格に標準化された操作手順を組み合わせることで、研究活動における再現性の最高水準を保証します。このアプローチにより、結果の一貫性と信頼性を維持し、研究成果に対する確信を育むことが可能となります。

InnoSerにおける行動テストの実施方法に関する詳細な背景情報

The study of human neurodegenerative and neuropsychiatric disorders in mouse models plays an indispensable role in understanding fundamental disease mechanisms. Mouse models of human neurodegenerative brain disorders such as Alzheimer’s and Parkinson’s disease, but also neurodevelopmental disorders like STXBP1 epileptic encephalopathy, are used in preclinical studies to evaluate the efficacy of therapeutic compounds.  

To evaluate a therapeutic compound’s efficacy against such indications, standardized, in-depth and well-controlled behavioural rodent studies are needed. While such behavioural tests are indispensable, they also represent one of the most challenging experimental set-ups. Inconsistent results reported among different laboratories suggest that many variables need to be considered, to prevent irreproducible results and decrease unnecessary labour where possible.  

InnoSerは、高度に標準化され、再現性が高く、堅牢な従来型行動アッセイを採用しています。各標準化行動アッセイについて、InnoSerの科学者は神経変性疾患および神経精神疾患の各げっ歯類モデルに対し詳細な表現型解析を実施しました。このデータは観察可能な多くの行動表現型の基準値として機能し、クラウドベースデータベースAHCODAのユーザーがアクセス可能ですTMのユーザーがアクセス可能です。  

To reduce the potential interference of animal handling before and during the behavioural assay, scientists at InnoSer work with multiple conventional and proprietary self-developed automated behavioural assays. Automated home-cages collect a wealth of longitudinal behavioural phenotyping data in a highly standardized manner, without the need for human intervention. Automated home-cages have additional advantages, relating to both efficiency of the experiment, but also the influence on rodent’s behaviour.  

Determining the efficacy profile through behavioural readouts 

Determining the efficacy of a candidate drug typically requires a combination of functional behavioural readouts (i.e., motor function, cognitive function and assessment of anxiety or social behaviour) combined with biological readouts (i.e., organ collection, blood and/or CSF collection followed up with histopathology and bioanalyses).  

Behavioural testing provides crucial insights into the underlying disease mechanisms, as well as readouts that can be used for preclinical efficacy studies. This allows drug developers to determine the efficacy, safety as well as potential adverse effects of such compounds before progressing to clinical trials.